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Abstract 
The treatment or prevention of bleeding in patients with hemophilia A rely on replacement 
therapy with different factor VIII containing products or on the use of by-passing agents, i.e., 
activated prothrombin complex concentrates or recombinant activated factor VII. Emerging 
approaches include the use of bispecific anti-factor IXa/factor X antibodies, anti-Tissue Factor 
Pathway Inhibitor antibodies, interfering RNA to antithrombin, APC-specific serpins or gene 
therapy. The latter strategies however meet with short term clinical experience and potential 
adverse effects including the absence of tight temporal and spatial control of coagulation or risk 
for uncontrolled insertional mutagenesis. The systemic delivery of mRNA allows the 
endogenous production of the corresponding encoded protein. Thus, injection of lipid 
nanoparticles-formulated erythropoietin-encoding mRNA resulted in increased erythropoiesis 
in mice and macaques. Here, we demonstrate that a single injection of in vitro transcribed B 
domain-deleted factor VIII-encoding mRNA to factor VIII-deficient mice allows the 
endogenous production of pro-coagulant factor VIII. Circulating FVIII:C levels above 5% of 
normal levels were maintained for up to 72 hours, with an estimated half-life of factor VIII 
production of 17.9 hours, and corrected the bleeding phenotype in a tail clipping assay. The 
endogenously produced factor VIII however exhibited low specific activity and induced a 
potent neutralizing IgG response upon repeated administration of the mRNA. Our results 
suggest that the administration of mRNA is a plausible strategy for the endogenous production 
of proteins characterized by poor translational efficacy. At term, the use of alternative mRNA 
delivery systems and improved factor VIII-encoding mRNA should foster the production of 
functional molecules and reduce their immunogenicity.  
 
Keywords: Hemophilia A, factor VIII, in vitro transcribed mRNA, mRNA therapy 
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Article Summary 
1. We investigated whether the systemic delivery to FVIII-deficient mice of in vitro 
transcribed mRNA encoding FVIII allows the endogenous production of procoagulant 
FVIII.  
2. The systemic delivery of FVIII-encoding mRNA yielded therapeutic levels of 
circulating FVIII, but induced a brisk neutralizing immune response.  
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Introduction 
Hemophilia A is a rare X-linked hemorrhagic disorder that results from insufficient plasma 
levels of pro-coagulant factor VIII (FVIII).1 Replacement therapy using exogenous FVIII is to 
date the most efficient strategy to treat or prevent bleeds. It is however extremely expensive 
owing to the elevated production costs and short half-life of therapeutic FVIII and need for life-
long treatment. Several alternative strategies to correct bleeding include the use of FVIII by-
passing agents, such as activated prothrombin complex concentrates (aPCC), recombinant 
factor VIIa (rFVIIa) or monoclonal FVIII-mimicking bispecific antibodies,2 the injection of 
anti-Tissue Factor Pathway Inhibitor (TFPI)3, of interfering RNA to antithrombin (AT)4 or of 
APC-specific serpins,5 and gene therapy.6 Each of these promising therapies has however 
intrinsic challenges that may limit broad application at term.  
The in vivo production of proteins following the administration of mRNA was demonstrated in 
the early 90’s in the case of luciferase and beta-galactosidase,7 leading to the first clinical trial 
with mRNA a decade later.8 Concomitantly, both double- and single-stranded RNA were found 
to trigger innate immunity upon ligation of TLR3, 7 and 8, and RIG-1.9-12 The replacement of 
uridines by 1-methylpseudouridines and the removal of double-stranded RNA by HPLC was 
demonstrated to abrogate the activation of innate immune cells,13, 14 and allowed the in vivo 
production of different proteins, including erythropoietin (EPO), factor IX and anti-HIV 
antibodies without the induction of overt neutralizing immune responses.15-19 Conversely, the 
administration of synthetic mRNA was also used in vaccination strategies either by direct 
injection20 or upon adoptive transfer of ex vivo transfected dendritic cells.21, 22  
Because of its monogenic nature and the requirements for low amounts of FVIII to correct the 
bleeding phenotype of the patients, hemophilia A is a particularly suitable disease for treatment 
with mRNA. Furthermore, transfection with mRNA is by essence not integrative, and thus 
avoids risks of uncontrolled insertional mutagenesis that may occur in DNA-based gene therapy 
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approaches. In addition, mRNA is translated only transiently and is degraded by physiological 
pathways, thus ensuring its safety and facilitating the control of the bio-availability of the 
encoded protein. Here, we investigated whether the intravenous administration of FVIII-
encoding mRNA allows the production of therapeutic levels of pro-coagulant FVIII in FVIII-
deficient mice.  
 
Methods 
Cloning of FVIII 
The cDNA encoding human B domain-deleted (BDD) FVIII (FVIIIHSQ), containing the 14-
amino acid segment SFSQNPPVLKRHQR in place of the B domain, cloned in the ReNeo 
mammalian expression plasmid with a geneticin resistance, has been described previously.23 
Codon optimization of the DNA sequence encoding human BDD-FVIII was adapted to the bias 
of Homo Sapiens using an in-house proprietary software (GeneOptimizer) from GeneArt 
(Thermo Fisher, Darmstadt, Germany). The GeneOptimizer software also calculates removal 
of cis-acting sequence motifs, including internal TATA-boxes, chi-sites and ribosomal entry 
sites, AT- or GC-rich sequence stretches, AU-rich elements, inhibitory and cis-acting repressor 
sequence elements, repeat sequences, RNA secondary structures, and all cryptic splice sites. 
The codon optimized BDD-FVIII-encoding cDNA was also cloned in the ReNeo vector.  
 
In vitro transcription of mRNA 
mRNAs were transcribed as previously described15 using the linearized plasmids encoding 
BDD-FVIII (FVIIIHSQ), the codon-optimized BDD-FVIII (CoFVIIIHSQ) and firefly luciferase 
(Luciferase). The Megascript T7 RNA polymerase kit (Thermo Fisher) was used for 
transcription, and UTP was replaced with 1-methylpseudouridine triphosphate (m1ΨTP; 
TriLink, San Diego, CA) to generate m1Ψ-containing mRNA. All mRNAs were transcribed to 
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contain 100-nt long poly(A) tails. To obtain cap1, RNA was incubated with guanylyltransferase 
and 2´-O-methyltransferase (Vaccinia capping system; New England Biolabs, Frankfurt). All 
mRNAs were purified and stored at -20°C. 
  
In vitro transfection 
For transient in vitro production of FVIII, baby hamster kidney (BHK) cells (0.5 million cells 
in 48-well plates) were transfected with FVIIIHSQ or CoFVIIIHSQ cloned in the ReNeo vector 
(0.1 µg) using lipofectamine (Invitrogen, Carlsbad, CA, USA). For in vitro transfection using 
mRNA, mRNA (0.4 µg) was mixed with TransIT®-mRNA reagent (0.45 µl, Mirus Bio, 
Madison, WI, USA) and Boost reagent (0.29 µl) in a final volume of 50 µl of Dulbecco’s 
Modified Eagle’s Medium for 2 min at room temperature. HEK293 cells (50,000 cells/130 µL) 
were incubated with the formulated mRNA overnight in DMEM-F12 (DMEM-F12, Thermo 
Fisher). FVIII was measured in the supernatant after 24 hours. Supernatant was kept frozen at 
-80°C until use.  
 
Treatment of mice 
Mice were 8 to 12-week-old FVIII exon 16 knock-out C57BL/6 mice (a kind gift from Prof 
H.H. Kazazian, Department of Genetics, University of Pennsylvania School of Medicine, 
Philadelphia, PA, USA). Mice were injected intravenously with recombinant BDD-FVIII 
(rFVIII, Refacto®, Pfizer, 150 IU/kg), or with mRNA (1 to 5 µg) formulated in TransIT® (100 
to 350 µL final volume). Blood was collected from retro-orbital sinus 6, 24, 48, 72 or 120 hours 
following the injection of mRNA. Plasma was kept frozen at -80°C until use. Animals were 
handled in agreement with local ethical authorities (Approval by ethics committee Charles 
Darwin, ethical authorization #3335 2015121718044892). FVIII:Ag, FVIII:C, anti-FVIII IgG 
and FVIII inhibitors were measured as described in Supplemental Methods online.  
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Results 
Codon-optimization of cDNA encoding FVIIIHSQ improves in vitro FVIII production 
We first investigated whether codon-optimization of FVIIIHSQ improves the production of FVIII 
by BHK transfected cells. To this end, the codon-optimized cDNA encoding B domain-deleted 
FVIII (CoFVIIIHSQ) was synthesized and inserted in the Reneo vector. BHK cells were 
transiently transfected with 0.1 µg FVIIIHSQ or CoFVIIIHSQ-encoding cDNA (Figure 1A). 
FVIII:Ag and FVIII:C were measured in the supernatant 24 hours later by ELISA and 
chromogenic assay. Transfection with CoFVIIIHSQ-encoding cDNA produced 4.2-fold more 
FVIII:Ag (mean±SEM: 0.11±0.01 IU/mL vs 0.03±0.00 IU/mL, respectively, P<0.01) and 4.8-
fold more FVIII:C (0.14±0.02 IU/mL vs 0.03±0.01 IU/mL, respectively, P<0.01), than 
transfection with the non-optimized FVIIIHSQ-encoding cDNA. Our data confirm previous 
findings obtained upon gene therapy in preclinical models of hemophilia A,24, 25 on the capacity 
of codon optimization to increase the yields of FVIII production. 
 
Transfection with FVIII-encoding mRNA leads to FVIII production in vitro 
We then validated the capacity of mRNA transcribed in vitro using the FVIIIHSQ and 
CoFVIIIHSQ-encoding cDNA as templates, to promote FVIII production. As the codon-
optimization is for Homo Sapiens, mRNA encoding FVIIIHSQ or CoFVIIIHSQ formulated in 
TransIT® were used to transfect human HEK293 cells (Figure 1B). As a negative control, 
HEK293 cells were transfected with luciferase-encoding mRNA. Transfection with the two 
FVIII-encoding mRNA lead to the in vitro production of FVIII to similar amounts (FVIII:Ag - 
0.28±0.03 IU/mL vs 0.36±0.04 IU/mL for FVIIIHSQ and CoFVIIIHSQ, respectively) and similar 
activities (FVIII:C - 0.20±0.01 IU/mL vs 0.24±0.02 IU/mL, respectively). Accordingly, the 
specific activity of FVIII produced using both mRNA did not differ (0.72±0.06 and 0.68±0.08, 
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respectively), suggesting that codon optimization has no beneficial effect on the production of 
FVIII when cells are transfected with mRNA, in our experimental system.  
 
Systemic delivery of FVIII-encoding mRNA to FVIII-deficient mice leads to the 
endogenous production of FVIII 
FVIII-deficient mice were injected intravenously with 1 µg FVIIIHSQ or CoFVIIIHSQ-encoding 
mRNA formulated in TransIT® (Figure 2A). Plasma levels of FVIII:Ag and FVIII:C, measured 
after 24 hours, were 1.00±0.15 IU/mL and 0.34±0.07 IU/mL in the case of FVIIIHSQ-encoding 
mRNA, and 1.30±0.19 IU/mL and 0.36±0.06 IU/mL in the case of CoFVIIIHSQ-encoding 
mRNA. Likewise, the specific activities of FVIIIHSQ and CoFVIIIHSQ (defined as the ratios of 
FVIII:C over FVIII:Ag) did not differ significantly: 0.31±0.06 and 0.25±0.02, respectively, but 
were more than 2-fold lower than specific activities measured in vitro (Figure 1B). To 
investigate for the presence of non-functional FVIII molecules, we measured plasma levels of 
FVIII light chain using a dedicated ELISA. Levels of FVIII:Ag and light chain were perfectly 
correlated (Figure 2B: slope=1.15±0.10, P<0.0001). However, 14 of the 20 tested samples 
showed >10% more FVIII light chain than total FVIII, indicating that some FVIII in the plasma 
samples was missing its A2 domain (A2 domain dissociation is a feature of FVIII 
inactivation26).  
The endogenous production of FVIII was then followed over 72 hours after the injection of 1, 
3 or 5 µg of CoFVIIIHSQ-encoding mRNA. At 24 hours (Figure 3A, left panel), the levels of 
FVIII:C reached in the circulation ranged from 0.27±0.11 to 0.42±0.14 IU/mL. The effect of 
the dose of injected mRNA on the level of endogenously produced FVIII was statistically 
significant at 72 hours (Figure 3A, right panel). Interestingly, the mean residual FVIII activity 
72 hours after the injection of 3 and 5 µg of mRNA, was above 5% of the theoretical FVIII:C 
in normal plasma (0.06±0.02 IU/mL and 0.11±0.03 IU/mL, respectively). We then estimated 
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the total amount of FVIII:C produced over 72 hours following injection of FVIII-encoding 
mRNA. To this end, mice were injected intravenously either with 3 IU of human rFVIII or with 
3 µg of CoFVIIIHSQ-encoding mRNA formulated in TransIT® (Figure 3B). The areas under the 
curves depicting the changes in FVIII:C plasma levels over time were 2.9 and 17.8 
IU/mL x hours, respectively, showing that the injection of 3 µg of mRNA allows the 
endogenous production over a period of 72 hours of amounts of FVIII:C 6-fold greater than the 
amount of rFVIII injected at once. The half-life of rFVIII in the circulation was fitted using a 
two-phase decay equation: short and long half-lives of 0.9 and 4.7 hours were calculated. An 
apparent half-life for the production of FVIII of 17.9 hours was calculated by fitting the FVIII:C 
levels measured at 24, 48 and 72 hours with a one-phase decay equation.  
 
Correction of the bleeding phenotype of FVIII-deficient mice by the endogenously 
produced FVIII 
We then investigate the effect of a single injection of FVIII-encoding mRNA on the bleeding 
phenotype of FVIII-deficient mice. FVIII-deficient mice were injected with PBS, with FVIII-
encoding mRNA or with 1.2 or 3 IU rFVIII (Figure 4). The tip of the mouse tails was clipped 
after 30 minutes in the case of rFVIII or after 24 hours in the case of PBS or mRNA, which 
correspond to the activity peak of each individual treatment. Blood loss was followed over 
20 min. While the PBS-injected mice lost 274.3±53.4 µL of blood, injection of rFVIII protected 
the mice from major bleeding with blood loss of 86.0±44.9 µL and 12.2±0.9 µL for 1.2 IU 
(P<0.05) and 3 IU (P<0.001) rFVIII, respectively. Interestingly, mice injected with FVIII-
encoding mRNA loss 45.8±24.6 µL of blood (P<0.001 as compared to PBS-treated mice), 
showing correction of the bleeding phenotype. 
 
Multiple injections of FVIII-encoding mRNA trigger an anti-FVIII immune response 
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The repeated administration of rFVIII is known to trigger the production of inhibitory anti-
FVIII IgG in mice after 3-5 injections.27 We thus assessed the effect of multiple injections of 
FVIII-encoding mRNA on the onset of an anti-FVIII immune response. We treated FVIII-
deficient mice with 1 µg FVIII-encoding mRNA once a week for 7 weeks. As a control, FVIII-
deficient mice were injected once a week with 5 IU rFVIII. First, we measured residual plasma 
FVIII levels 24 hours after rFVIII or mRNA injection (Figures 5A and B). Consistent with the 
short half-life of FVIII in mice, very low FVIII:Ag and FVIII:C were measured in plasma 
24 hours following injection of rFVIII during the first 3 weeks of treatment. In the case of 
mRNA-treated mice, a sharp decrease in both FVIII:Ag and FVIII:C was observed between the 
first (1.13±0.23 IU/mL and 0.37±0.11 IU/mL, respectively) and second (0.26±0.06 IU/mL and 
0.05±0.05 IU/mL, respectively) injections. From the third week of treatment onwards, FVIII:C 
levels were below detection levels.  
We then investigated the presence of inhibitory anti-FVIII IgG 5 days after each administration 
of mRNA or rFVIII to the mice (Figures 5C and 5D). As described previously, the intravenous 
administration of rFVIII induced a progressive increase in levels of anti-FVIII IgG that reached 
a plateau after 5 injections (10168±4501 AU after 7 injections, Figure 5C). This was mirrored 
by a gradual increase in levels of FVIII inhibitors, that crossed 10 BU/mL 5 days after the fourth 
injection to plateau at 111±79 BU/mL (Figure 5D). In the case of FVIII-encoding mRNA, levels 
of anti-FVIII IgG as high as those obtained after 5 injections of rFVIII were detected as early 
as 5 days following the second treatment. The plateau after 7 weeks of treatment 
(98060±8251 AU) was 10-fold higher in the case of mRNA than in that of rFVIII. Likewise, 
while no FVIII inhibitory activity was detected 5 days after the first injection of mRNA, levels 
of 383±196 BU/ml were generated 5 days after the second injection, which gradually increased 
to reach a plateau at 2258±669 BU/mL after 7 weeks of treatment. The plateau of FVIII 
inhibitors was thus 20-fold greater in mice treated with mRNA than in mice treated with rFVIII. 
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Of note, the incubation FVIII-encoding mRNA, TransIT or TransIT-formulated mRNA with 
immature human MODCs failed to induce the production of TNF-alpha and IL-6 (Figures 5E 
and 5F), indicating that mRNA and TransIT® do not activate innate immune cells and are not 
responsible for the triggering of the anti-FVIII immune response. In additional experiments, we 
investigated the site of production of mRNA-encoded proteins following formulation in 
TransIT®. To this end, Balb/c mice were injected with luciferase-encoding mRNA formulated 
in TransIT. The luminescence measured 24 hours later was at least 2 folds greater in the spleen 
as compared to the liver (supplemental Figure S1), suggesting that the liver and hepatocytes are 
not the main target for TransIT-formulated mRNA. Attempts to detect FVIII in FVIII-encoding 
mRNA-treated FVIII-deficient mice lead to occasional FVIII signal in the marginal zone of the 
spleen and constant absence of FVIII detection in the liver (data not shown).  
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Discussion 
The present work documents the sustained endogenous production of pro-coagulant FVIII 
following the injection of FVIII-encoding mRNA into FVIII-deficient mice, and is of potential 
relevance for the improvement of treatments for hemophilia A patients. FVIII levels achieved 
24 hours after the injection of mRNA were about 40% of the levels in normal plasma. The 
expression levels of FVIII are notoriously low owing to poor transcriptional and translation 
efficacies27-29 as well as retention of the protein in the ER.30, 31 Attempts to improve the levels 
of expression of FVIII include the partial removal of the B domain with conservation of 
essential N-glycosylation sites,24, 31 mutation of a BiP binding site32 to ensure improved transfer 
from ER to Golgi,33 and codon optimization. Here, mRNA was generated using wild-type23 or 
codon-optimized cDNA encoding human BDD-FVIII. While codon optimization improved 
FVIII production following transfection of eukaryotic cells with plasmid DNA in vitro, it did 
not increase the levels of FVIII:C or FVIII:Ag following in vitro mRNA transfection of cells 
or in vivo transfection of FVIII-deficient mice. Codon optimization aims at improving 
translation rates by using codons for which the cognate tRNA levels are not limiting. Thus, 
codon optimization of FVIII-encoding cDNA cloned in lentiviral vectors or adenoviral-
associated vectors lead to more than 10-fold increased FVIII levels after in vitro transfection of 
cell lines and after injection to wild-type or FVIII-deficient mice.24, 25 The lack of improvement 
in protein production associated with the administration of codon-optimized mRNA encoding 
FVIII suggests that codon optimization of FVIII preferentially targets transcriptional rather than 
translational events, as previously shown.34, 35 Alternatively, levels of mRNA introduced in 
each cell upon in vivo transfection with TransIT® may be much lower than that transcribed 
endogenously following transfection using DNA, and insufficient to exhaust non-abundant 
tRNA. Increasing the amount of mRNA injected in vivo had however no drastic effect on the 
FVIII levels reached in the circulation.  
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Frequent spontaneous joint and muscle bleeds in patients with severe hemophilia A eventually 
lead to the development of arthropathy and functional joint impairment. An association between 
joint bleeds and baseline FVIII activity levels was demonstrated,36 with FVIII levels above 5% 
of the normal values drastically reducing the occurrence of joint bleeds. Because the half-life 
of human FVIII in patients with hemophilia A is comprised between 12 and 18 hours, 
prophylactic replacement therapy is the gold standard to maintain healthy joint functions.37 In 
FVIII-deficient mice, the half-life of human FVIII is comprised between 4 and 6 hours. 
Interestingly, delivery of FVIII-encoding mRNA yielded FVIII levels that corrected acute 
bleeding in a tail clipping assay, and were maintained above 5% for up to 72 hours. The longer 
residence time of FVIII produced after mRNA delivery as compared to that of recombinant 
FVIII results from the cumulative lifespans of the transfected mRNA in the cells and of the 
FVIII released in the circulation. The mRNA-based therapy can be improved by engineering 
the encoded protein to extend its half-life.38 For instance, a FVIII molecule with an increased 
half-life has been developed upon fusion of FVIII to the Fc fragment of human IgG1.2 We 
anticipate that the use of mRNA encoding long-lasting FVIII glycoproteins will allow a further 
increase in the duration of FVIII detection in vivo. Because peak expression levels of FVIII 
were reached in the mice between 6 and 24 hours after the administration of mRNA, mRNA-
based therapy may represent a surrogate for prophylactic treatment rather than for the on-
demand treatment of sudden acute hemorrhagic events.  
The specific activity of the recombinant FVIII produced by eukaryotic cells in vitro was about 
1.2 following transfection using cDNA and about 0.7 following transfection with mRNA. In 
contrast, the specific activity of the FVIII produced endogenously following injection of mRNA 
to the mice was about 0.3, suggesting the absence of pro-coagulant activity for a substantial 
proportion of the endogenously produced FVIII molecules. In parallel, we compared the levels 
of intact FVIII measured using a standard ELISA, wherein FVIII is captured with an anti-light 
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chain antibody and detected with anti-heavy chain antibody, with that of FVIII light chain 
measured using a sandwich light chain-specific ELISA. A perfect correlation was obtained 
although with an overall tendency for 2-fold more light chains than intact molecules. 
Importantly, the levels of light chain may be under-estimated owing to the short in vivo half-
life of the light chain alone. Future experiments will indicate whether the use of mRNA 
encoding FVIII lacking the furin cleavage site39, 40 between the heavy and light chains, or FVIII 
mutants with increased FVIII A2 subunit stability41 yields FVIII with improved specific 
activity. An alternative and non-exclusive explanation for the poor specific activity of the 
endogenously produced FVIII is the fact that the TransIT® used to formulate the mRNA does 
not target particular cell types. In fact, we show here that luciferase is produced by the spleen, 
rather than by the liver, following injection of mice with luciferase-encoding mRNA formulated 
with TransIT®. Accordingly, immunofluorescence experiments on mice treated with FVIII-
encoding mRNA occasionally detected faint amounts of FVIII in the marginal zone of the 
spleen but never in the liver (not shown). Hence, TransIT® delivers FVIII mRNA to cells that 
are not dedicated to the production of FVIII,42, 43 thus potentially generating FVIII molecules 
that are improperly folded or have undergone incorrect post-translational modifications.  
In patients with severe hemophilia A, inhibitory anti-FVIII IgG (FVIII inhibitors) generally 
develop within the first 20 cumulated days of exposure to therapeutic FVIII.44 In the present 
work, and in agreement with previous studies in FVIII-deficient mice,45 FVIII-binding IgG and 
FVIII inhibitors were detected after 2 and 3 intravenous injections of recombinant FVIII, 
respectively. The levels of anti-FVIII IgG increased to reach a plateau at 10 to 100-fold higher 
levels after 2 to 3 additional injections of recombinant FVIII. In the case of mRNA 
administration however, close to maximal levels of FVIII-binding IgG and inhibitory antibodies 
were reached after only two injections of FVIII-encoding mRNA. Accordingly, endogenous 
FVIII:C was undetectable as early as after the second administration of mRNA. Different 
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explanations for such a brisk and intense immune response to the endogenously produced FVIII 
may be envisaged. Because the mRNA used in our study was engineered to contain 1-
methylpseudouridines and was HPLC-purified to remove dsRNA, thus abrogating mRNA 
recognition by TLR3, TLR7, TLR8 and RIG-I,9-12 it is not probable that the very mRNA plays 
an adjuvant role in the onset the anti-FVIII immune response. Indeed, FVIII-encoding mRNA, 
alone or formulated in TransIT®, failed to activate human immature MODCs in vitro. 
Interestingly, previous work on in vivo mRNA transfection without apparent induction of 
neutralizing immune responses have used TransIT®15 or other types of nanoparticles.16, 18 Most 
studies were however performed in immuno-compromised animals46 or in animal expressing 
the corresponding endogenous protein (e.g., the absence of induction of an anti-EPO immune 
response in animals receiving EPO-encoding mRNA15, 17 probably relates to the presence of the 
endogenous EPO molecule and associated ongoing active immune tolerance). 
In fact, the very formulation of mRNA in TransIT® may be a reason for induction of a strong 
anti-FVIII immune response. TransIT® was initially conceived for in vitro and not in vivo gene 
transfection. As explained above, protein production following injection of TransIT®-
formulated mRNA is not targeted to the liver and not to endothelial cells, that produce FVIII 
under physiological conditions. This is reminiscent of the early works on gene therapy for 
hemophilia wherein the use of promoters with poor specificity for hepatocytes was associated 
with the induction of neutralizing anti-FVIII or anti-factor IX antibodies47.  
Several lines of evidence suggest that the produced FVIII itself may be responsible for the sharp 
anti-FVIII immune response. As explained above, FVIII is a particularly immunogenic 
glycoprotein: e.g., a fusion protein between the light chain of FVIII and the first domain of 
hemagglutinin 1 (HA1) demonstrated greater anti-HA1 immunogenicity upon intravenous 
injection to FVIII-deficient mice than the HA1 molecule alone.48 In contrast, the production of 
factor IX was induced in mice following administration of mRNA without report of a 
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neutralizing immune response.18 Of note, a relationship between the dose of FVIII injected and 
the kinetics of detection of the anti-FVIII IgG response was reported in mice45 and in patients.49 
This is particularly relevant in view of the fact that the amount of active FVIII produced over 
72 hours after one injection of FVIII-encoding mRNA was equivalent to 6 folds the amount of 
recombinant FVIII administered in a single injection. Furthermore, based on the poor specific 
activity of the endogenously produced FVIII, the total amount of FVIII molecules (active and 
inactive) probably exceeds 18 folds that of injected recombinant FVIII. Further work will 
indicate whether targeting mRNA delivery to hepatocytes or to endothelial cells using improved 
lipid nanoparticle-based formulating agents,50 using mRNA encoding single chain or A2 variant 
stable FVIII39, 40, 41 and including miRNA target sequences to prevent off-target expression in 
hematopoietic cells51 are plausible strategies to improve the specific activity and reduce the 
immunogenicity of the endogenously produced molecule. 
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Legends to figures 
Figure 1. In vitro production of wild-type and codon-optimized FVIII. DNA in lipofectamin 
(0.1 µg, panels A) or mRNA formulated in TransIT® (0.4 µg, panels B) encoding BDD-FVIII 
(FVIIIHSQ) and codon-optimized BDD-FVIII (CoFVIIIHSQ) were used to transfect BHK (panels 
A) or HEK293 (panels B) cells. mRNA encoding luciferase was used as a control (panels B). 
FVIII:Ag (left panels) and FVIII:C (middle panels) were measured in cell supernatant 24 hours 
after transfection. The right panels depict the specific activities as calculated by dividing the 
FVIII:C values by the FVIII:Ag values. Statistical differences were assessed using a two-tailed 
t test (ns: non-significant, *: p<0.05, **: p<0.01, ***:p<0.001). Results are depicted as 
means±SEM for 3 independent experiments. 
 
Figure 2. Delivery of FVIII-encoding mRNA allows endogenous production of FVIII. 
mRNA encoding BDD-FVIII (FVIIIHSQ) or codon-optimized BDD-FVIII (CoFVIIIHSQ) was 
formulated in TransIT®. FVIII-deficient mice were then injected intravenously with 1 µg 
FVIII-encoding mRNA. Panel A. FVIII:Ag and FVIII:C were measured in plasma after 
24 hours. Individual symbols on the graphs represent individual mice; horizontal bars represent 
means±SEM. Statistical differences were assessed using a two-tailed t test (ns: non-significant). 
Panel B. FVIII:Ag and FVIII light chain were measured in plasma by ELISA. Individual 
symbols on the graphs represent individual mice. The full line curve represents the linear 
regression of the experimental data. The dotted line represents the theoretic correlation with a 
slope of 1.  
 
Figure 3. Time-dependent production of endogenous FVIII after a single injection of 
FVIII-encoding mRNA. mRNA encoding codon-optimized BDD-FVIII (CoFVIIIHSQ) was 
formulated in TransIT®. Panel A. FVIII-deficient mice were then injected intravenously with 
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1, 3 or 5 µg FVIII-encoding mRNA. FVIII:C was measured in plasma after 24 and 72 hours. 
Individual symbols on the graphs represent individual mice; horizontal bars represent 
means±SEM. The dotted line indicates the critical FVIII level (i.e., 5%) required to drastically 
reduce joint bleeds. Statistical differences were assessed using a two-tailed t test (ns: non-
significant, *: p<0.05). Panel B. Mice were injected with 3 µg CoFVIIIHSQ-encoding mRNA 
formulated in TransIT®, or with 100 µl of 10 nM recombinant BDD-FVIII (3 IU rFVIII). 
FVIII:C in plasma was measured after 30, 60, 90, 120, 180, 240, 360, 390 and 480 min in the 
case of rFVIII, and 6, 24, 48 and 72 hours (excluding the 0 and 6-hour time-points) in the case 
of mRNA. The dotted line depicts the non-linear fit (two-phase exponential decay: y=0.62*e-
0.15x+0.2211*e-0.80x) of the experimental data obtained with rFVIII. The full circles and full line 
curve represent means±SEM of 6 mice treated with mRNA (representative of 2 independent 
experiments; fitted with a one-phase exponential decay for the values obtained at 24, 48 and 72 
hours: y=0.99*e-0.03874x). Areas under the curves were calculated using Prism GraphPad 
(Version 6).  
 
Figure 4. Injection of FVIII-encoding mRNA corrects acute bleeding in FVIII-deficient 
mice. FVIII-deficient mice were injected intravenously with 3 µg of FVIII-encoding mRNA 
(empty squares) formulated in TransIT®, with 1.2 IU (empty circles) or 3 IU (full diamonds) 
recombinant BDD-FVIII (rFVIII) or with PBS (full triangles). Mice tails were clipped 3 mm 
from the tip, 24 hours after mRNA and PBS injection, or 30 min after rFVIII injection. Bleeding 
intensity was measured as the volume of blood lost during 20 min. Horizontal bar depict means 
and individual dots representing individual mice. Statistical differences were assessed using the 
double-sided Mann-Whitney test (ns: non-significant; *: p<0.05; ***: p<0.001). 
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Figure 5. Induction of an anti-FVIII immune response after repeated injections of FVIII-
encoding mRNA. FVIII-deficient mice were injected intravenously with 1 µg of coFVIIIHSQ-
encoding mRNA formulated in TransIT® (full circles), or with 5 IU recombinant BDD-FVIII 
(empty squares), once a week for 7 weeks. FVIII:Ag (panel A) and FVIII:C (panel B) were 
measured in plasma 24 hours after each injection. Anti-FVIII IgG (panel C) and inhibitory titers 
(panel D) were measured in plasma 72 hours after each injection. Results are depicted as 
mean±SEM for 4-7 mice per group. The vertical dotted lines represent the days of FVIII/mRNA 
administration. The horizontal dotted lines represent the background levels (calculated as 
“mean + 1 x SD”) measured in 6-7 FVIII-deficient mice (panel A, 0.045+0.013 IU/mL; panel 
B, 0.001±0.000 IU/mL; panel C, 0.84±0.23 µg/ml); or the threshold for detection (panel D, 5 
BU/mL). Panels E and F. Five-day old immature MODCs were incubated alone (Untreated) or 
in the presence of Poly:IC, LPS, TransIT® alone, 1 µg FVIII-encoding mRNA (mRNA) alone 
or 1 µg FVIII-encoding mRNA formulated in TransIT®. The panels show the levels of TNF-
alpha (panel E) and IL-6 (panel F) measured in the culture supernatant 8 (full bars) and 24 
(empty bars) hours later. Data depict means±SEM from 2 independent experiments. Differences 
between TransIT, mRNA, TransIT+mRNA and Untreated were not statistically significant 
(two-sided Mann-Whitney test).  
